Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial
- Attard, G
- Sydes, MR
- Mason, MD
- Clarke, NW
- Aebersold, D
- de Bono, JS
- Dearnaley, DP
- Parker, CC
- Ritchie, AWS
- Russell, JM
- Thalmann, G
- Cassoly, E
- Millman, R
- Matheson, D
- Schiavone, F
- Spears, MR
- Parmar, MKB
- James, ND
Publication date
June 2014
DOI Publisher
Elsevier BV ISSN
0302-2838 Citation count (estimate)
24Abstract
There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure. © 2014 European Association of Urology
Add to ORKG